Edition:
India

Alexion Pharmaceuticals Inc (ALXN.OQ)

ALXN.OQ on NASDAQ Stock Exchange Global Select Market

106.51USD
8:51pm IST
Change (% chg)

$-0.62 (-0.58%)
Prev Close
$107.13
Open
$107.37
Day's High
$107.78
Day's Low
$105.91
Volume
99,651
Avg. Vol
753,172
52-wk High
$141.81
52-wk Low
$92.57

Latest Key Developments (Source: Significant Developments)

Alexion Pharmaceuticals Q2 Non-GAAP Earnings Per Share $2.64
Wednesday, 24 Jul 2019 

Alexion Pharmaceuticals Inc ::ALEXION REPORTS SECOND QUARTER 2019 RESULTS.Q2 NON-GAAP EARNINGS PER SHARE $2.64.Q2 GAAP EARNINGS PER SHARE $2.04.Q2 REVENUE $1.203 BILLION VERSUS REFINITIV IBES ESTIMATE OF $1.17 BILLION.Q2 EARNINGS PER SHARE ESTIMATE $2.34 -- REFINITIV IBES DATA.ALEXION PLANS TO FILE FOR REGULATORY APPROVALS IN EU AND JAPAN IN SECOND HALF OF 2019.PLANS TO INITIATE A PHASE 3 STUDY OF ULTOMIRIS IN NMOSD BY END OF 2019, PENDING REGULATORY FEEDBACK.INCREASING FY TOTAL REVENUES AND EPS GUIDANCE.ALEXION PHARMACEUTICALS - DOSING IS UNDERWAY IN A SINGLE, PK-BASED PHASE 3 STUDY OF ULTOMIRIS, DATA ARE EXPECTED IN EARLY 2020.SEES FY TOTAL REVENUES $4,750 MILLION TO $4,800 MILLION.PLANS TO INITIATE A PHASE 3 STUDY OF ULTOMIRIS IN HSCT-TMA IN FIRST HALF OF 2020, PENDING REGULATORY FEEDBACK.SEES FY EARNINGS PER SHARE $8.13 TO $8.41.SEES FY ADJUSTED EARNINGS PER SHARE $9.65 TO $9.85.FY2019 EARNINGS PER SHARE VIEW $9.44, REVENUE VIEW $4.78 BILLION -- REFINITIV IBES DATA.  Full Article

Alexion Pharmaceuticals Receives Marketing Authorization From EC For Ultomiris For Adults With PNH
Wednesday, 3 Jul 2019 

July 3 (Reuters) - Alexion Pharmaceuticals Inc ::ULTOMIRIS® (RAVULIZUMAB) RECEIVES MARKETING AUTHORIZATION FROM EUROPEAN COMMISSION FOR ADULTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH).ALEXION PHARMACEUTICALS - EC APPROVAL BASED ON RESULTS FROM TWO PHASE 3 STUDIES.  Full Article

Alexion Pharma Reports Positive Extension Data From Late-Stage Study of Ultomiris In Patients With Paroxysmal Nocturnal Hemoglobinuria
Friday, 14 Jun 2019 

June 14 (Reuters) - Alexion Pharmaceuticals Inc ::POSITIVE PHASE 3 EXTENSION DATA FOR ULTOMIRIS® (RAVULIZUMAB) IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) PRESENTED AT EUROPEAN HEMATOLOGY ASSOCIATION (EHA) CONGRESS.ALEXION PHARMACEUTICALS INC - ULTOMIRIS DEMONSTRATED CONSISTENT EFFICACY AND SAFETY THROUGH 52 WEEKS.ALEXION PHARMACEUTICALS - SUSTAINED EFFICACY OF ULTOMIRIS WAS OBSERVED ON CO-PRIMARY ENDPOINTS OF TRANSFUSION AVOIDANCE & NORMALIZATION OF LDH LEVELS.ALEXION PHARMACEUTICALS - MOST COMMON ADVERSE EVENTS OCCURRED LESS FREQUENTLY IN EXTENSION PHASE THAN DURING INITIAL TREATMENT PHASE FOR ULTOMIRIS.ALEXION PHARMACEUTICALS - SUSTAINED EFFICACY OF ULTOMIRIS WAS OBSERVED ON SECONDARY ENDPOINTS OF LDH LEVEL REDUCTION AND BREAKTHROUGH HEMOLYSIS.  Full Article

Alexion Pharmaceuticals Posts Q1 Earnings Per Share Of $2.61
Thursday, 25 Apr 2019 

April 25 (Reuters) - Alexion Pharmaceuticals Inc ::ALEXION REPORTS FIRST QUARTER 2019 RESULTS.Q1 NON-GAAP EARNINGS PER SHARE $2.39.Q1 GAAP EARNINGS PER SHARE $2.61.Q1 REVENUE $1.14 BILLION VERSUS REFINITIV IBES ESTIMATE OF $1.13 BILLION.Q1 EARNINGS PER SHARE ESTIMATE $2.19 -- REFINITIV IBES DATA.SEES FY 2019 TOTAL REVENUES IN RANGE $4,675 MILLION TO $4,750 MILLION.ALEXION IS INCREASING TOTAL REVENUES AND EPS GUIDANCE.SEES FY 2019 GAAP EPS IN RANGE $6.76 TO $7.96.SEES FY 2019 NON-GAAP EPS IN RANGE $9.25 TO $9.45.FY2019 EARNINGS PER SHARE VIEW $9.31, REVENUE VIEW $4.75 BILLION -- REFINITIV IBES DATA.  Full Article

Alexion And Zealand Pharma Announce Pact To Discover And Develop Peptide Therapies
Wednesday, 20 Mar 2019 

March 20 (Reuters) - Alexion Pharmaceuticals Inc ::ALEXION AND ZEALAND PHARMA ANNOUNCE COLLABORATION TO DISCOVER AND DEVELOP PEPTIDE THERAPIES FOR COMPLEMENT-MEDIATED DISEASES.ZEALAND PHARMA A/S - COLLABORATION FURTHERS ALEXION'S COMPLEMENT LEADERSHIP WITH EXPANSION INTO PEPTIDE THERAPIES.ZEALAND-AGREEMENT PROVIDES ALEXION EXCLUSIVE WORLDWIDE LICENSES FOR 1 PRECLINICAL TARGET, OPTION FOR UP TO 3 ADDITIONAL TARGETS, IN COMPLEMENT PATHWAY.ZEALAND - TO RECEIVE UPFRONT PAYMENT OF $25 MILLION & EQUITY INVESTMENT OF $15 MILLION, WITH POTENTIAL FOR ADDITIONAL MILESTONE-DEPENDENT & ROYALTY PAYMENTS.ZEALAND PHARMA A/S - WILL LEAD JOINT DISCOVERY AND RESEARCH EFFORTS THROUGH PRECLINICAL STAGE.ZEALAND PHARMA A/S - ALEXION WILL LEAD DEVELOPMENT EFFORTS BEGINNING WITH IND FILING AND PHASE 1 STUDIES.ZEALAND PHARMA A/S - FOR LEAD TARGET, AGREEMENT PROVIDES POTENTIAL FOR DEVELOPMENT-RELATED MILESTONES OF UP TO $115 MILLION.ZEALAND-FOR LEAD TARGET AGREEMENT PROVIDES UP TO $495 MILLION IN SALES-RELATED MILESTONES, POTENTIAL FOR HIGH SINGLE- TO LOW DOUBLE-DIGIT ROYALTY PAYMENTS.  Full Article

Alexion Announces Interim Data From Phase 3 Study Of Soliris In Adults With Generalized Myasthenia Gravis In Muscle & Nerve
Friday, 8 Mar 2019 

March 8 (Reuters) - Alexion Pharmaceuticals Inc ::ALEXION ANNOUNCES PUBLICATION OF INTERIM DATA FROM PHASE 3 OPEN-LABEL EXTENSION STUDY SUPPORTING LONG-TERM EFFICACY AND SAFETY OF SOLIRIS® (ECULIZUMAB) IN ADULT PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS IN MUSCLE & NERVE.ALEXION - NEW DATA SUGGEST POSITIVE IMPACT ON SUSTAINED LONG-TERM CLINICAL BENEFIT FOR ADULT PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS IN MUSCLE & NERVE.  Full Article

Alexion Says FDA Grants Priority Review & Accepts sBLA Of SOLIRIS As Treatment For Patients With NMOSD
Saturday, 23 Feb 2019 

Feb 22 (Reuters) - Alexion Pharmaceuticals Inc ::FDA GRANTS PRIORITY REVIEW AND ACCEPTS SBLA OF SOLIRIS® (ECULIZUMAB) AS A TREATMENT FOR PATIENTS WITH NEUROMYELITIS OPTICA SPECTRUM DISORDER (NMOSD).ALEXION PHARMACEUTICALS INC - FDA SETS ACTION DATE OF JUNE 28, 2019.ALEXION PHARMACEUTICALS INC - FILING IN EUROPEAN UNION UNDER REVIEW, AND FILING IN JAPAN PLANNED FOR Q1 2019.  Full Article

Temasek Holdings Cuts Share Stake In Amazon.Com, Takes in Total SA
Thursday, 14 Feb 2019 

Feb 14 (Reuters) - Temasek Holdings (Private) Ltd::TEMASEK HOLDINGS (PRIVATE) LTD CUTS SHARE STAKE IN AMAZON.COM BY 46.6 PERCENT TO 35,153 SHARES- SEC FILING.TEMASEK HOLDINGS (PRIVATE) LTD TAKES SHARE STAKE IN TOTAL SA OF 460,885 SPONSORED ADR.TEMASEK HOLDINGS (PRIVATE) LTD CUTS SHARE STAKE IN ALEXION PHARMACEUTICALS INC BY 49.7 PERCENT TO 616,630 SHARES.TEMASEK HOLDINGS (PRIVATE) LTD - CHANGE IN HOLDINGS ARE AS OF DECEMBER 31, 2018 AND COMPARED WITH PREVIOUS QUARTER ENDED AS OF SEPTEMBER 30, 2018.  Full Article

Alexion Reports Fourth Quarter And Full Year 2018 Results
Monday, 4 Feb 2019 

Feb 4 (Reuters) - Alexion Pharmaceuticals Inc ::ALEXION REPORTS FOURTH QUARTER AND FULL YEAR 2018 RESULTS.Q4 NON-GAAP EARNINGS PER SHARE $2.14.Q4 GAAP LOSS PER SHARE $0.20.Q4 REVENUE $1.129 BILLION VERSUS REFINITIV IBES ESTIMATE OF $1.06 BILLION.Q4 EARNINGS PER SHARE ESTIMATE $1.82 -- REFINITIV IBES DATA.SEES FY 2019 GAAP EARNINGS PER SHARE $6.14 TO $7.26.SEES FY 2019 REVENUE $4.625 BILLION TO $4.7 BILLION.SEES FY 2019 NON-GAAP EARNINGS PER SHARE $9.10 TO $9.30.ALEXION PHARMACEUTICALS - FILED U.S. & EU SUBMISSIONS FOR SOLIRIS IN NEUROMYELITIS OPTICA SPECTRUM DISORDER & ON TRACK TO FILE IN JAPAN LATER IN 2019.FY2019 EARNINGS PER SHARE VIEW $8.73, REVENUE VIEW $4.75 BILLION -- REFINITIV IBES DATA.SEES 2019 TOTAL REVENUES $4,625 TO $4,700 MILLION.SEES 2019 SOLIRIS/ULTOMIRIS REVENUES $3,970 TO $4,020 MILLION.FY2019 REVENUE VIEW $4.75 BILLION -- REFINITIV IBES DATA.  Full Article

Fortress Biotech Announces CAEL-101 Strategic Partnership With Alexion Pharmaceuticals
Thursday, 31 Jan 2019 

Jan 31 (Reuters) - Fortress Biotech Inc ::FORTRESS BIOTECH ANNOUNCES CAEL-101 STRATEGIC PARTNERSHIP WITH ALEXION PHARMACEUTICALS.FORTRESS BIOTECH INC - FORTRESS-FOUNDED CAELUM BIOSCIENCES TO RECEIVE $60 MILLION IN A STRATEGIC EQUITY INVESTMENT AND OPTION FEE.FORTRESS BIOTECH INC - ALEXION HAS OPTION TO ACQUIRE CAELUM BIOSCIENCES BASED ON PHASE 2 DATA.FORTRESS BIOTECH - UNDER TERMS ALEXION WILL ACQUIRE A MINORITY EQUITY INTEREST IN CAELUM AND AN EXCLUSIVE OPTION TO ACQUIRE REMAINING EQUITY IN CO.FORTRESS BIOTECH INC - COLLABORATION ALSO PROVIDES FOR POTENTIAL ADDITIONAL PAYMENTS OF UP TO $500 MILLION IN EVENT ALEXION EXERCISES ACQUISITION OPTION.FORTRESS BIOTECH INC - ALEXION AND CAELUM WILL COLLABORATE ON DESIGN OF ONGOING DEVELOPMENT PROGRAM FOR CAEL-101.  Full Article

FDA approves Alexion's Ultomiris for another rare blood disease

The U.S. Food and Drug Administration on Friday approved Alexion Pharmaceuticals Inc's treatment for a second rare blood disorder, the company said.